Roles of microRNAs in the Development of Osteoporosis in Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed to evaluate the roles of specific miRNAs in osteoporosis in men.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Circulating miRNA in Primary Hyperparathyroidism

NCT03931109

Primary Hyperparathyroidism Osteoporosis, Postmenopausal

COMPLETED

Development of Intervention Model for Osteoporosis and Fall Prevention in Taiwan

NCT01206491

Osteoporosis

UNKNOWN

Fracture and Fall Prevention in Elderly With Osteoporosis

NCT01844154

Osteoporosis, Osteopenia

UNKNOWN

Study on the microRNA Expression Level in Postmenopausal Osteoporosis

NCT02128009

Postmenopausal Osteoporosis

COMPLETED

Vitamin D Status and Multi-Omics Profiles in Primary Osteoporosis

NCT07296471

Primary Osteoporosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the past, osteoporosis is usually viewed as a woman disease. However, men and women are shown to lose their bone mass at the same rate by more than 65 of age, and osteoporosis in men causes higher mortality in men than those in women. Thus, osteoporosis in men has recently aroused public attention. Androgen deficiency was the main cause leading to osteoporosis. Bone structure is maintained by a dynamic balance of osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Androgens and androgen receptor (AR) play critical roles in regulation of bone formation and resorption. MicroRNAs (miRNAs) are non-coding small RNAs and participate in regulating activities of osteoblasts and osteoclasts by postranslationally targeting certain gene expressions. miR-133 and -135 can target BMP-2, Runx2, and Smad5 and then regulate osteoblast differentiation. Likewise, miR-141 and -200a negatively regulated osteoblast differentiation. Nevertheless, the functional roles of miRNAs in osteoporosis in men are still unknown. In addition, miRNA are stable and can be detected in the blood as novel biomarkers for certain diseases. A recent study analyzed the levels of miRNAs in circulating monocytes of 10 high and 10 low bone mineral density postmenopausal Caucasian women and found miR-133a is a potential biomarker for postmenopausal osteoporosis. In comparison, the roles of blood miRNAs in osteoporosis in men have not been evaluated. Therefore, this study is aimed to evaluate the roles of specific miRNAs in osteoporosis in men.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal

bone mineral density T\>=-1.0

Osteopenia

Intervention Type OTHER

bone mineral density -1.0\>T\>=-2.5

Osteoporosis

Intervention Type OTHER

bone mineral density T\<-2.5

Osteopenia

bone mineral density -1.0\>T\>=-2.5

Normal

Intervention Type OTHER

bone mineral density T\>=-1.0

Osteoporosis

Intervention Type OTHER

bone mineral density T\<-2.5

Osteoporosis

bone mineral density T\<-2.5

Normal

Intervention Type OTHER

bone mineral density T\>=-1.0

Osteopenia

Intervention Type OTHER

bone mineral density -1.0\>T\>=-2.5

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal

bone mineral density T\>=-1.0

Intervention Type OTHER

Osteopenia

bone mineral density -1.0\>T\>=-2.5

Intervention Type OTHER

Osteoporosis

bone mineral density T\<-2.5

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Twenty oriental men (mean age, 80 years; age range, 70-90 years).
2. Candidates have no clinical evidence or history of focal lesions of the femur; previous hip surgery or irradiation; hip trauma; spinal trauma.
3. Participants who have thoroughly understood and signed the consent form.
4. Ten normal adult male (age range, 20-40 years).

Exclusion Criteria

1. Participants with secondary causes of osteoporosis, such as thyroid, parathyroid disease, osteogenesis imperfect and osteomalacia.
2. Participants with Paget's disease, serious liver disease, serious renal disease (indicated by a serum creatinine concentration of more than 1.6mg/dL).
3. Participants who currently or have history of using steroids or hormone replacement therapy.
4. Participants who fail to sign to the consent form.

Minimum Eligible Age

70 Years

Maximum Eligible Age

90 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes